Navigation Links
15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
Date:11/14/2011

MOUNTAIN VIEW, Calif., Nov. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that new analyses from TA-314, a phase 3 long-term safety and efficacy study of the investigational drug avanafil for the treatment of erectile dysfunction (ED), was presented over the weekend at the 2011 Sexual Medicine Society of North America (SMSNA) Meeting in Las Vegas, NV.  Andrew R. McCullough, MD, Professor of Surgery/Urology at Albany Medical College, presented the analysis of results from the study that showed that avanafil was effective in as early as 15 minutes after dosing when analyzed both by subject and attempt.  Of the subjects attempting intercourse </=15 minutes of dosing, 83% had successful intercourse.  Additionally, eighty percent (80%) of all study-wide sexual attempts made within 15 minutes of dosing were successful.

The study entitled, "An Open-label, Long-term Evaluation of the Safety and Efficacy of Avanafil in Men with Erectile Dysfunction" was presented during the Late Breaking Trials Session on November 12, 2011.  Dr. McCullough concluded that based on the results of the study, this onset of action suggests that avanafil, if approved, is potentially well-suited for on-demand treatment in men with mild to severe ED.

About AvanafilAvanafil is an investigational oral drug being developed for the treatment of erectile dysfunction.  Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma Corporation.  VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian Pacific Rim countries.

About VIVUSVIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health.  The company's lead investigational product in c
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
9. Phase 1b/2a Program Commences for RVX-208
10. Chiltern Early Phase: Fully Integrated and Business Ready
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2015)... Phenome Networks, a software-as-a-service plant ... availability, beginning May 31st, of its next-generation Phenome One ... solidifies Phenome Networks’ lead in the plant breeding market, ... intuitive breeding workflow based on years of experience with ... design, and more. The new version of Phenome One, ...
(Date:5/22/2015)... Knowledgent , the data and analytics ... potential of big data analytics in the life sciences ... help life sciences and healthcare organizations understand the ways ... business insights. , The life sciences and healthcare industries ... patient profiling, compliance and regulatory requirements, and scientific research. ...
(Date:5/21/2015)... PLAINSBORO, N.J. (PRWEB) May 21, 2015 ... initial circulation audit and been admitted to BPA ... result, BPA Worldwide will track audience data for ... geographic coverage. , “By becoming a member ... steadfast dedication to providing our clients with the ...
(Date:5/21/2015)... 2015  The EveryLife Foundation for Rare Diseases ... Amy Klobuchar (D-MN) today for introducing ... Treatments, or OPEN ACT. Supported by ... this bipartisan legislation promises to rapidly bring hundreds ... disease patients by incentivizing drug makers to "repurpose" ...
Breaking Biology Technology:Phenome Networks Announces its Next Generation Plant Breeding Management and Analytics Software 2Phenome Networks Announces its Next Generation Plant Breeding Management and Analytics Software 3New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2
... New Hire - Tony Mallia, Practice DirectorFAIRFAX, Va., Feb. ... pleased to announce the addition to our team of ... manage the methodology for enterprise engineering, bringing to bear ... large organizations in the federal and financial services sectors. ...
... OLIGOMERIX, Inc. today announced the receipt of a ... $323,000 from the National Institute on Aging of the ... program is to develop novel biomarker assays for Alzheimer,s ... apolipoprotein E (apoE) proteins will be monitored in cerebrospinal ...
... Picoplatin in Combination with Docetaxel/Prednisone as First-Line ... Results To Be Presented at the American ... Symposium -SOUTH SAN FRANCISCO, Calif., Feb. 25 ... PARD ), a biopharmaceutical company focused on ...
Cached Biology Technology:Edmond Scientific Company 'Spotlight on the Executive': 2OLIGOMERIX Awarded NIH Grant to Develop Novel Biomarkers for Alzheimer's Disease 2Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer 2Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer 3Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer 4Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer 5
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... MA -- A high level of air pollution, in the form ... people exposed to it, according to a unique new study of ... on long-term data compiled for the first time, and projects that ... are set to lose an aggregate 2.5 billion years of life ...
... that extend from their unicellular bodies. Some bacteria, including the ... the human gut, have multiple flagella that rotate as a ... acrobatically by unbundling their flagella, causing the cell to tumble, ... microbes, including 90 percent of motile marine bacteria, have only ...
... have helped boost green foliage across the world,s arid ... called CO2 fertilisation, according to CSIRO research., In findings ... Australian National University (ANU), found that this CO2 fertilisation ... cover from 1982-2010 across parts of the arid areas ...
Cached Biology News:Innovative MIT study estimates extent to which air pollution in China shortens human lives 2Innovative MIT study estimates extent to which air pollution in China shortens human lives 3Innovative MIT study estimates extent to which air pollution in China shortens human lives 4Buckling up to turn 2Buckling up to turn 3Buckling up to turn 4Deserts 'greening' from rising CO2 2
... TempliPhi 500 Amplification Kit, 500 reactions. ... sequencing in 4-6 h.Generate microgram quantities ... of starting material.Use amplified DNA directly ... from bacterial or M13 liquid cultures, ...
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
Mixing speed from 750-3200RPM, small vortexing orbit of1.0mm...
This Universal 24" X 18" (61 X 45.7cm.) shaker platforms will accept any Thermo Forma shaker flask clip....
Biology Products: